Beijing Beilu Pharmaceutical Co Ltd

Beilu Pharmaceutical maintains a relatively strong liquidity position, with a current ratio of 2.4, indicating that it has 2.4 times more current assets than current liabilities. However, the company's liquidity is rated as medium, and its cash and equivalents amount to only 1.85 million CNY, which is significantly lower than its long-term debt of 531.68 million CNY. This suggests that the company may need to rely on operating cash flow or external financing to meet long-term obligations. In terms of profitability, Beilu Pharmaceutical reports a return on equity (ROE) of 4.11% and a return on assets (ROA) of 2.77%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, which often sees ROE and ROA in the double-digit range. The company's net income of 92.73 million CNY is derived from a gross profit of 542.96 million CNY, indicating a gross margin of approximately 45%. While this margin is reasonable, it is not exceptional for the sector. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. This lack of diversification could pose a risk if demand for its core products declines. Geographically, the company is primarily focused on the Chinese market, and there is no indication of significant international operations or revenue diversification. Looking at growth, Beilu Pharmaceutical's capital expenditures for the period were negative at -218.87 million CNY, suggesting a reduction in investment in physical assets. This could indicate a strategic shift or financial constraints. The company's free cash flow is also negative at -70.41 million CNY, which may limit its ability to reinvest in growth opportunities or return value to shareholders. The risk assessment highlights a key liquidity flag: the company's net cash position is negative after accounting for total debt. This suggests that the company's cash reserves are insufficient to cover its long-term obligations, which could increase its reliance on external financing. However, the risk of dilution is rated as low, indicating that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders. There are no recent filings or transcripts provided in the available data to indicate any material events or strategic shifts. The company appears to be operating within a stable but potentially constrained financial environment.